Home Drug IndexClinical Monograph

Ondansetron Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antiemetic

Subclass

5-HT3 (Serotonin) receptor antagonist

Speciality

Gastroenterology

Schedule (India)

Schedule H

Routes

Oral, Intravenous, Intramuscular

Formulations

Tablets: 4 mg, 8 mg
Orally Disintegrating Tablets (ODT): 4 mg, 8 mg
Oral Solution/Syrup: 2 mg/5 mL
Injection: 2 mg/mL (2 mL ampoule = 4 mg; 4 mL ampoule = 8 mg)

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Chemotherapy-Induced Nausea and Vomiting (CINV) — Adults

A. Moderately Emetogenic Chemotherapy:

Parameter	Recommendation
Starting dose	8 mg orally or IV 30 minutes before chemotherapy
Titration	Not applicable
Usual maintenance dose	8 mg orally every 8–12 hours for 1–2 days post-chemotherapy
Maximum dose	24 mg/day orally; single IV dose not to exceed 16 mg

B. Highly Emetogenic Chemotherapy (with dexamethasone):

Parameter	Recommendation
Starting dose	8 mg IV 30 minutes before chemotherapy (with dexamethasone 12–20 mg IV)
Titration	Not applicable
Usual maintenance dose	8 mg orally twice daily for 1–2 days
Maximum dose	Single IV dose 16 mg; total daily dose 24 mg

Clinical Notes:

Always combine with dexamethasone for highly emetogenic regimens
For multi-day chemotherapy, continue ondansetron for each treatment day plus 1–2 days after
NK1 receptor antagonist (aprepitant) may be added for highly emetogenic regimens if available

2. Postoperative Nausea and Vomiting (PONV) — Adults

Parameter	Recommendation
Starting dose (Prophylaxis)	4 mg IV at induction of anaesthesia OR at end of surgery
Titration	Not applicable
Usual maintenance dose	Single dose usually sufficient; may repeat 4 mg if vomiting recurs
Maximum dose	16 mg/day

Treatment of Established PONV:

Parameter	Recommendation
Dose	4 mg IV as single dose
Repeat dosing	May repeat after 4–6 hours if needed
Maximum dose	16 mg/day

Clinical Notes:

More effective for preventing vomiting than nausea
Consider combination with dexamethasone 4–8 mg IV for high-risk patients

3. Radiotherapy-Induced Nausea and Vomiting — Adults

Parameter	Recommendation
Starting dose	8 mg orally 1–2 hours before each radiotherapy fraction
Titration	Not applicable
Usual maintenance dose	8 mg orally twice daily on radiotherapy days
Maximum dose	24 mg/day

Clinical Notes:

Higher doses may be required for total body irradiation or upper abdominal radiation
Continue for 1–2 days after completion of radiation if nausea persists

Secondary Indications – Adults Only (Off-label)

Indication	Dose	Duration	Supervision	Evidence Basis
Hyperemesis Gravidarum — OFF-LABEL	4–8 mg orally TDS or 4 mg IV BD	Until symptoms controlled; short-term use preferred	Specialist only (Obstetrics)	Indian obstetric practice; use when first-line agents (doxylamine-pyridoxine, promethazine) fail
Opioid-Induced Nausea/Vomiting — OFF-LABEL	4–8 mg orally or IV TDS	Duration of opioid therapy	General use acceptable	Palliative care protocols; clinical experience
Pruritus in Cholestasis — OFF-LABEL	4–8 mg orally TDS	As required	Specialist only (Gastroenterology)	Limited evidence; Indian hepatology practice

Paediatric indications''

PAEDIATRIC DOSING (Specialist Only)

Primary Indications

1. Chemotherapy-Induced Nausea and Vomiting

Age Restriction: Not recommended below 6 months of age except under specialist oncology supervision.

Intravenous Dosing:

Body Weight	IV Dose (Single)	Timing	Maximum Single Dose
<10 kg	0.1 mg/kg	30 minutes before chemotherapy	—
10–40 kg	0.15 mg/kg OR 4 mg	30 minutes before chemotherapy	8 mg
>40 kg	8 mg (adult dose)	30 minutes before chemotherapy	8 mg per dose

Oral Dosing:

Body Surface Area	Oral Dose	Frequency	Maximum Daily Dose
<0.6 m²	2 mg	Every 12 hours for 1–2 days	4 mg/day
0.6–1.2 m²	4 mg	Every 12 hours for 1–2 days	8 mg/day
>1.2 m²	8 mg	Every 12 hours for 1–2 days	16 mg/day

2. Postoperative Nausea and Vomiting

Parameter	Recommendation
Starting dose	0.1 mg/kg IV (maximum 4 mg)
Timing	At end of anaesthesia or when nausea occurs
Titration	Not applicable
Maximum dose	4 mg per dose

Clinical Notes:

Single dose usually sufficient
Slow IV administration over 2–5 minutes preferred
ECG monitoring if QT prolongation risk factors present

Secondary Indications – Paediatric (Off-label)

Indication	Age	Dose	Duration	Notes	Evidence Basis
Acute Gastroenteritis with Vomiting — OFF-LABEL	≥6 months	0.15 mg/kg orally (max 4 mg)	Single dose; may repeat once after 8 hours	Use only in moderate-severe vomiting preventing oral rehydration	IAP guidelines; WHO supportive; multiple RCTs

Important Restrictions:

Not for routine use in mild viral gastroenteritis
Should not replace oral rehydration therapy
Assess for red flags (bilious vomiting, dehydration, altered sensorium) before prescribing

Age Restriction Statement:
Not recommended below 6 months of age except under specialist supervision (paediatric oncology/critical care).

Safety Monitoring:

Monitor for QT prolongation in children with electrolyte disturbances
Observe for constipation, especially with repeated dosing
Watch for extrapyramidal symptoms (rare)

Renal Adjustments

No dose adjustment required in renal impairment (mild, moderate, or severe).

Dialysis:

Haemodialysis: No supplemental dose required; ondansetron not significantly dialysed
Peritoneal dialysis: No adjustment required

Note: Use with standard monitoring; metabolites may accumulate in severe renal impairment but clinical significance is unclear.

Hepatic adjustment

Contraindications

Known hypersensitivity to ondansetron or other 5-HT3 receptor antagonists (granisetron, palonosetron)
Concomitant use with apomorphine — risk of profound hypotension and loss of consciousness
Congenital long QT syndrome

Cautions

Pre-existing QT interval prolongation or risk factors for QT prolongation
Electrolyte abnormalities — hypokalaemia, hypomagnesaemia (correct before use)
Concomitant use of other QT-prolonging drugs
Bradyarrhythmias or heart failure
Hepatic impairment (reduced clearance)
Subacute intestinal obstruction — may mask symptoms
Recent abdominal surgery — may reduce lower GI motility
Patients receiving other serotonergic drugs — risk of serotonin syndrome

Pregnancy

Parameter	Details
Risk category	Limited human data; some studies suggest possible increased risk of orofacial clefts with first-trimester use — not definitively established
Preferred alternatives	First-line: Doxylamine + Pyridoxine combination; Second-line: Promethazine, Metoclopramide
When may be used	May be used when first-line agents fail; hyperemesis gravidarum refractory to other treatment; benefit must outweigh potential risk
Monitoring	Monitor maternal QT interval if used with other drugs; fetal growth monitoring as per standard antenatal care

Lactation'

Parameter	Details
Compatibility	Compatible with breastfeeding
Drug levels in milk	Low (estimated infant dose <5% of maternal weight-adjusted dose)
Preferred alternatives	Single-dose or short-term use preferred; domperidone or metoclopramide also options
Infant monitoring	Observe for drowsiness, constipation, feeding difficulties (rare)

Elderly

Parameter	Recommendation
Starting dose	4 mg orally or IV; start at lower end of dosing range
Titration	Not typically required; assess response before increasing
Maximum dose	16 mg/day preferred; avoid doses >16 mg/day
Special risks	Increased risk of QT prolongation; higher prevalence of electrolyte abnormalities; increased constipation risk; assess baseline ECG in cardiac patients

Note: No specific pharmacokinetic changes in elderly with normal organ function, but increased sensitivity to adverse effects.

Major drug interactions

Drug/Class	Mechanism/Effect	Recommendation
Apomorphine	Profound hypotension and loss of consciousness	Contraindicated — avoid combination
Class IA antiarrhythmics (quinidine, procainamide)	Additive QT prolongation	Avoid combination; if unavoidable, ECG monitoring mandatory
Class III antiarrhythmics (amiodarone, sotalol)	Additive QT prolongation → risk of torsades de pointes	Avoid if possible; ECG monitoring if used together
Haloperidol, droperidol	QT prolongation risk	Use with caution; monitor ECG
High-dose methadone	Additive QT prolongation	Monitor ECG; correct electrolytes
Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine)	Reduced ondansetron plasma levels → decreased efficacy	May need higher ondansetron dose or alternative antiemetic

Moderate drug interactions

Drug/Class	Effect	Recommendation
CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin)	Increased ondansetron levels → increased QT risk	Monitor for adverse effects; consider dose reduction in hepatic impairment
SSRIs (fluoxetine, sertraline, paroxetine)	Possible serotonin syndrome; minor QT effect	Monitor for serotonin syndrome symptoms; usually safe in short-term use
SNRIs (venlafaxine, duloxetine)	Possible serotonin syndrome	Monitor as above
Tramadol	Ondansetron may reduce tramadol analgesic efficacy; serotonin syndrome risk	Monitor pain control; may need alternative analgesic
Dexamethasone	Used therapeutically together; no pharmacokinetic interaction	Standard combination for CINV prophylaxis
Loop/Thiazide diuretics	Hypokalaemia may increase QT prolongation risk	Monitor potassium levels
Fluoroquinolones (levofloxacin, moxifloxacin)	Additive QT prolongation	Use with caution; ECG if risk factors present

Common Adverse effects

Headache (most common)
Constipation
Fatigue / asthenia
Dizziness
Flushing / warmth sensation
Injection site reactions (pain, erythema with IV/IM)
Diarrhoea (paradoxical)
Transient visual disturbances

Serious Adverse effects

Adverse Effect	Clinical Action
QT prolongation / Torsades de pointes	Discontinue immediately; ECG monitoring; correct electrolytes; manage arrhythmia
Serotonin syndrome	Discontinue ondansetron and other serotonergic drugs; supportive care; may require hospitalisation
Anaphylaxis / Severe hypersensitivity	Immediate discontinuation; emergency management
Stevens-Johnson Syndrome / TEN	Very rare; discontinue immediately; dermatology referral; hospitalisation
Transient blindness	Rare; typically resolves within 48 hours; reported mainly with IV use
Hepatotoxicity	Rare; usually mild transaminase elevation; discontinue if significant

Monitoring requirements

Baseline:

ECG in high-risk patients (elderly, cardiac disease, QT-prolonging drugs, electrolyte disturbances)
Serum electrolytes (potassium, magnesium) in patients with risk factors
Liver function tests if hepatic impairment suspected

After Initiation:

Clinical response — vomiting control, ability to tolerate oral intake
Assess hydration status
Monitor for constipation, especially with repeated dosing
ECG if QT-prolonging drugs added or electrolyte abnormalities develop

Long-term (if used repeatedly):

Periodic electrolyte monitoring
Liver function tests if prolonged use
Bowel function assessment

Brands in India

Single-Ingredient Formulations:

Emeset (Cipla)
Ondem (Alkem)
Vomikind (Mankind)
Zofran (GSK) — originator brand
Zondan (Dr. Reddy's)
Onset (Sun Pharma)
Emigo (Torrent)
Emitron (FDC)
Osetron (Cadila)

ODT Formulations:

Emeset MD (Cipla)
Ondem MD (Alkem)

Note: Fixed-dose combinations not commonly used; single-agent preferred for flexibility in dosing.

Price range (INR)

Formulation	Approximate Price
Tablet 4 mg (per tablet)	₹2–₹8
Tablet 8 mg (per tablet)	₹4–₹12
ODT 4 mg (per tablet)	₹4–₹10
ODT 8 mg (per tablet)	₹6–₹15
Injection 4 mg/2 mL (per ampoule)	₹8–₹25
Injection 8 mg/4 mL (per ampoule)	₹15–₹40
Syrup 30 mL	₹15–₹35

Included in NLEM 2022
NPPA price ceiling applicable
Available through government supply for oncology programmes

Clinical pearls'

Combine with dexamethasone for CINV — ondansetron alone is less effective for highly emetogenic chemotherapy; combination significantly improves control
IV dose ceiling of 16 mg — single IV doses exceeding 16 mg associated with QT prolongation; older recommendations of 32 mg IV no longer supported
Severe hepatic impairment — maximum 8 mg/day due to reduced clearance and increased QT risk
Paediatric gastroenteritis use is off-label but evidence-supported — single oral dose can facilitate oral rehydration in children with persistent vomiting; not a substitute for ORS
ODT formulation advantage — dissolves on tongue without water; useful in patients with active vomiting or difficulty swallowing
Constipation is common — especially with repeated dosing; counsel patients and consider prophylactic laxatives in cancer patients on opioids
No benefit over metoclopramide for simple nausea — reserve for chemotherapy/radiotherapy/PONV; avoid routine use for non-specific nausea

Version

RxIndia v1.0 — 05 Jun 2025

Reference

- CDSCO approved product inserts
- Indian Pharmacopoeia
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine
- IAP Drug Formulary
- AIIMS Antiemetic Protocols
- WHO Model List of Essential Medicines (paediatric supportive)
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (supportive)
- Published RCTs and meta-analyses for off-label paediatric gastroenteritis use

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...